The EU-funded DRTB-HDT project will determine if two adjunctive host-directed therapies can prevent the poor outcomes of treatment in cases of RIF-R TB.

As the year comes to a close, we extend our warmest season's greetings to our esteemed partners, collaborators, and stakeholders.

The Sponsor team visited Dr. Celso Khosa and team at the Instituto Nacional de Saúde (INS) site in Mozambique on 25 and 26 May 2023.

As enrollment is underway on the DRTB-HDT study with more patients put on the study, we thought this would be the perfect time to release the first issue of our newsletter.

The Aurum Institute is pleased to announce the enrolment of the first participant in its clinical trial testing two host-directed therapies (HDTs) in patients with drug-resistant tuberculosis (DRTB-HDT). The milestone was reached by the study team at the Isango Lethemba TB Research Unit in Port Elizabeth, South Africa, under the direction of Dr Francesca Conradie....